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Preamble and Transition to ACC/AHA 
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC) and 
the American Heart Association (AHA) are to prevent cardio-
vascular diseases (CVDs); improve the management of peo-
ple who have these diseases through professional education 
and research; and develop guidelines, standards, and policies 
that promote optimal patient care and cardiovascular health. 
Toward these objectives, the ACC and AHA have collaborated 
with the National Heart, Lung, and Blood Institute (NHLBI) 
and stakeholder and professional organizations to develop 
clinical practice guidelines for assessment of cardiovascular 
risk, lifestyle modifications to reduce cardiovascular risk, 
management of blood cholesterol in adults, and management 
of overweight and obesity in adults.
In 2008, the NHLBI initiated these guidelines by sponsoring 
rigorous systematic evidence reviews for each topic by expert 
panels convened to develop critical questions (CQs), interpret 
the evidence, and craft recommendations. In response to the 
2011 report from the Institute of Medicine on the develop-
ment of trustworthy clinical guidelines,1 the NHLBI Advisory 
Council recommended that the NHLBI focus specifically on 
reviewing the highest-quality evidence and partner with other 
organizations to develop recommendations.2,3 Accordingly, in 
June 2013 the NHLBI initiated collaboration with the ACC 
and AHA to work with other organizations to complete and 
publish the 4 guidelines noted above and make them avail-
able to the widest possible constituency. Recognizing that the 
Expert Panels/Work Groups did not consider evidence beyond 
2011 (except as specified in the methodology), the ACC, 
AHA, and collaborating societies plan to begin updating these 
guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guidelines 
(Task Force) appointed a subcommittee to shepherd this tran-
sition, communicate the rationale and expectations to the writ-
ing panels and partnering organizations, and expeditiously 
publish the documents. The ACC/AHA and partner organi-
zations recruited a limited number of expert reviewers for 
fiduciary examination of content, recognizing that each docu-
ment had undergone extensive peer review by representatives 
of the NHLBI Advisory Council, key federal agencies, and 
scientific experts. Each writing panel responded to comments 
from these reviewers. Clarifications were incorporated where 
appropriate, but there were no substantive changes because 
the bulk of the content was undisputed.
Although the Task Force led the final development of these 
prevention guidelines, they differ from other ACC/AHA guide-
lines. First, as opposed to an extensive compendium of clinical 
information, these documents are significantly more limited in 
scope and focus on selected CQs on each topic, based on the 
highest-quality evidence available. Recommendations were 
derived from randomized trials, meta-analyses, and observa-
tional studies evaluated for quality and were not formulated 
when sufficient evidence was not available. Second, the text 
accompanying each recommendation is succinct, summa-
rizing the evidence for each question. The Full Panel/Work 
Group Reports include more detailed information about the 
evidence statements (ESs) that serve as the basis for recom-
mendations. Third, the format of the recommendations differs 
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from other ACC/AHA guidelines. Each recommendation has 
been mapped from the NHLBI grading format to the ACC/
AHA Classification of Recommendation/Level of Evidence 
(COR/LOE) construct (Table 1) and is expressed in both for-
mats. Because of the inherent differences in grading systems 
and the clinical questions driving the recommendations, align-
ment between the NHLBI and ACC/AHA formats is in some 
cases imperfect. Explanations of these variations are noted in 
the recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by the 
writing panels to manage relationships of authors with indus-
try and other entities (RWI) are outlined in the methods section 
of each panel report. These policies were in effect when this 
effort began in 2008 and throughout the writing process and 
voting on recommendations, until the process was transferred 
to ACC/AHA in 2013. In the interest of transparency, the 
ACC/AHA requested that panel authors resubmit RWI disclo-
sures as of July 2013. Relationships relevant to this guideline 
are disclosed in Appendix 1. None of the ACC/AHA expert 
reviewers had relevant RWI (Appendix 2). See Appendix 3 for 
a list of abbreviations used in the guideline.
Systematic evidence reports and accompanying summary 
tables were developed by the expert panels and NHLBI. The 
guideline was reviewed by the ACC/AHA Task Force and 
approved by the ACC Board of Trustees and the AHA Science 
Advisory and Coordinating Committee. In addition, ACC/
AHA sought endorsement from other stakeholders, including 
professional organizations. It is the hope of the writing panels, 
stakeholders, professional organizations, NHLBI, and Task 
Force that the guidelines will garner the widest possible reader-
ship for the benefit of patients, providers, and the public health.
These guidelines are meant to define practices that meet 
the needs of patients in most circumstances and are not a 
replacement for clinical judgment. The ultimate decision 
about care of a particular patient must be made by the 
healthcare provider and patient in light of the circum-
stances presented by that patient. As a result, situations 
might arise in which deviations from these guidelines may 
be appropriate. These considerations notwithstanding, in 
caring for most patients, clinicians can employ the recom-
mendations confidently to reduce the risks of atheroscle-
rotic CVD events.
See Tables 2 and 3 for an explanation of the NHLBI recom-
mendation grading methodology.
1.1. Scope of Guideline
See Table 4 for the Lifestyle Expert Work Group's CQs.
A healthy lifestyle is important in the prevention of CVD, 
the leading cause of morbidity and mortality worldwide. The 
intent of the Lifestyle Work Group (Work Group) was to eval-
uate evidence that particular dietary patterns, nutrient intake, 
and levels and types of physical activity can play a major role 
in CVD prevention and treatment through effects on modifi-
able CVD risk factors (ie, blood pressure [BP] and lipids). 
These ESs and recommendations may be used as appropriate 
in the management of hypercholesterolemia and hypertension. 
The target audience of the report is primary care providers.
This guideline is based on the Full Work Group Report, 
which is provided as an online-only data supplement to the 
guideline. The Full Work Group Report supplement contains 
background and additional material related to content, meth-
odology, evidence synthesis, rationale, and references and 
is supported by the NHLBI Systematic Evidence Review, 
which can be found at http://www.nhlbi.nih.gov/guidelines/
cvd_adult/lifestyle/.
Diet and physical activity interventions of interest to the 
Work Group that were not included in this report because of 
time and resource limitations were the following: calcium, 
magnesium, alcohol, cardiorespiratory fitness, single behav-
ioral intervention or multicomponent lifestyle interventions, 
the addition of lifestyle intervention to pharmacotherapy, and 
smoking. Outcomes of interest not covered in this evidence 
review were the following risk factors: diabetes mellitus (dia-
betes)- and obesity-related measurements, incident diabetes 
metabolic syndrome, high-sensitivity C-reactive protein, and 
other inflammatory markers. The Work Group was interested 
in reviewing the evidence for CVD outcomes in all of the 
CQs; however, the evidence for mortality and CVD outcomes 
was reviewed only in CQ2.
1.2. Methodology and Evidence Review
1.2.1. Scope of the Evidence Review
To formulate the nutrition recommendations, the Work Group 
used randomized controlled trials (RCTs), observational stud-
ies, meta-analyses, and systematic reviews of studies carried 
out in adults (≥18 years of age) with or without established 
coronary heart disease/CVD and with or without risk factors 
for coronary heart disease/CVD, who were of normal weight, 
overweight, or obese. The evidence review date range was 
1998 to 2009. To capture historical data or more recent evi-
dence, date ranges were changed for subquestions in some 
instances. The evidence date ranges are described clearly in 
each CQ section. The Work Group assessed the impact of both 
dietary patterns and macronutrient composition on plasma 
low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), and triglycerides and on 
systolic BP and diastolic BP over a minimum RCT interven-
tion period of 1 month in studies performed in any geographic 
location and research setting.
Overall, the Work Group emphasized dietary patterns rather 
than individual dietary components. Patterns were character-
ized by habitual or prescribed combinations of daily food 
intake. Dietary patterns offer the opportunity to characterize 
the overall composition and quality of the eating behaviors of 
a population (eg, Mediterranean-style dietary [MED] pattern). 
Eating patterns consist of various combinations of foods that 
may differ in macronutrient, vitamin, and mineral composi-
tions. The macronutrients saturated, trans, monounsaturated, 
and polyunsaturated fatty acids are particularly relevant for 
their effects on plasma lipids and lipoproteins. Dietary sodium 
and potassium are particularly relevant for their effects on BP. 
Epidemiological research has examined the dietary patterns of 
populations and identified associations between various pat-
terns and CVD risk factors and outcomes. Intervention studies 
have tested a priori hypotheses involving prescribed dietary 
patterns specifically formulated on the basis of these data (eg, 
Dietary Approaches to Stop Hypertension [DASH] or MED 
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patterns). Population-based prospective cohort studies and 
RCTs suggest that there are healthier overall dietary patterns 
(foods and/or their constituent macronutrient, vitamin, and 
mineral combinations) that are associated with lower risk of 
chronic diseases, including CVD and risk factors such as type 
2 diabetes and hypertension. We reviewed data exclusively on 
dietary intake rather than nutritional supplements provided 
in pharmaceutical preparations (eg, potassium pills), because 
nutritional supplements may not have similar effects and are 
not considered “lifestyle” interventions.
The Work Group focused on CVD risk factors to provide 
a free-standing Lifestyle document and to inform the Blood 
Cholesterol guideline4 and the hypertension panel. It also 
recognized that RCTs examining the effects on hard out-
comes (myocardial infarction, stroke, heart failure, and CVD-
related death) are difficult if not impossible to conduct for 
several reasons (eg, long-term adherence to dietary changes). 
However, the Work Group also supplemented this evidence 
on risk factors with observational data on hard outcomes for 
sodium. The Work Group prioritized topics for the evidence 
review and was unable to review the evidence on hard out-
comes for dietary patterns or physical activity.
For physical activity, substantial epidemiological evidence 
links higher levels of aerobic physical activity to lower rates 
of CVD and other chronic diseases, such as type 2 diabetes. 
Evidence indicates a dose-dependent inverse relationship 
between levels of physical activity and rates of CVD. The pro-
posed mechanisms mediating the relationship between physi-
cal activity and decreased CVD rates include beneficial effects 
on lipids, lipoproteins, BP, and type 2 diabetes. The search for 
evidence related to physical activity and CVD included only 
systematic reviews and meta-analyses of RCTs or individual 
Table 1. Applying Classification of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines 
do not lend themselves to clinical trials. Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is 
useful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior 
myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve 
direct comparisons of the treatments or strategies being evaluated.
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controlled clinical trials in adults (≥18 years of age) that were 
published from 2001 to 2011. For this CQ, the intervention 
was defined as physical activity interventions of any type.
Weight loss and maintenance are crucial for prevention and 
control of CVD risk factors. The Obesity Expert Panel simul-
taneously performed a systematic review of the evidence for 
weight management and CVD risk factors and outcomes.5 The 
primary intent of the Work Group's systematic review was to 
focus on the effects of diet and physical activity on CVD risk 
factors independent of effects on weight. Therefore, studies 
in which the primary outcome was weight loss or in which 
treatment was associated with >3% change in weight were 
excluded from the present review. However, the Work Group 
expects that recommendations from both evidence reviews 
will apply to many patients.
Because of limited resources and time, the Work Group 
could not review every study pertaining to lifestyle and CVD 
risk factors and outcomes. Priority was given to strong study 
design and a contemporaneous timeframe (1998 to 2009). 
However, there were instances in which the evidence review 
was extended beyond that timeframe. Landmark evidence on 
the effect of fatty acids on lipids was included back to 1990. 
The sodium evidence review included evidence through April 
2012, and the physical activity meta-analysis review was 
extended to May 2011. Given the expertise of Work Group 
Table 2. NHLBI Grading of the Strength of Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net benefit†  
 is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net  
  benefit is moderate to substantial, or there is high certainty 
that the net benefit is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that  
 there is a small net benefit.
D Recommendation against
There is at least moderate certainty based on evidence that  
 there is no net benefit or that risks/harms outweigh benefits.
E Expert opinion (“There is insufficient evidence or evidence  
  is unclear or conflicting, but this is what the Work Group 
recommends.”)
Net benefit is unclear. Balance of benefits and harms cannot  
  be determined because of no evidence, insufficient evidence, 
unclear evidence, or conflicting evidence, but the Work Group 
thought it was important to provide clinical guidance and make a 
recommendation. Further research is recommended in this area.
N No recommendation for or against (“There is insufficient  
 evidence or evidence is unclear or conflicting.”)
Net benefit is unclear. Balance of benefits and harms cannot  
  be determined because of no evidence, insufficient evidence, 
unclear evidence, or conflicting evidence, and the Work Group 
thought no recommendation should be made. Further research  
is recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned 
with the quality of the evidence; however, under some circumstances, there 
may be valid reasons for making recommendations that are not closely aligned 
with the quality of the evidence (eg, strong recommendation when the evidence 
quality is moderate, such as smoking cessation to reduce cardiovascular 
disease risk or ordering an ECG as part of the initial diagnostic work-up for a 
patient presenting with possible MI). Those situations should be limited and the 
rationale explained clearly by the Work Group.
†Net benefit is defined as benefits minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, 
National Heart, Lung, and Blood Institute.
Table 3. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
•	Well-designed, well-executed† RCT that adequately  
 represent populations to which the results are applied 
and directly assess effects on health outcomes.
•	Meta-analyses of such studies.
Highly certain about the estimate of effect. Further  
  research is unlikely to change our confidence in the 
estimate of effect.
High
•	RCT with minor limitations‡ affecting confidence in,  
or applicability of, the results.
•	Well-designed, well-executed nonrandomized  
 controlled studies§ and well-designed, well-executed  
observational studies‖.
•	Meta-analyses of such studies.
Moderately certain about the estimate of effect.  
  Further research may have an impact on our confidence 
in the estimate of effect and may change the estimate.
Moderate
•	RCT with major limitations.
•	Nonrandomized controlled studies and observational  
 studies with major limitations affecting confidence in,  
or applicability of, the results.
•	Uncontrolled clinical observations without an  
 appropriate comparison group (eg, case series,  
case reports).
•	Physiological studies in humans.
•	Meta-analyses of such studies.
Low certainty about the estimate of effect. Further  
  research is likely to have an impact on our  
confidence in the estimate of effect and is likely  
to change the estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (eg, 
jumping from airplanes or tall structures), can represent high- or moderate-
quality evidence. In such cases, the rationale for the evidence rating exception 
should be explained by the Work Group and clearly justified.
†“Well-designed, well-executed” refers to studies that directly address the 
question; use adequate randomization, blinding, and allocation concealment; 
are adequately powered; use intention-to-treat analyses; and have high 
follow-up rates.
‡Limitations include concerns with the design and execution of a study that 
result in decreased confidence in the true estimate of the effect. Examples 
of such limitations include but are not limited to: inadequate randomization, 
lack of blinding of study participants or outcome assessors, inadequate power, 
outcomes of interest that are not prespecified for the primary outcomes, 
low follow-up rates, and findings based on subgroup analyses. Whether the 
limitations are considered minor or major is based on the number and severity 
of flaws in design or execution. Rules for determining whether the limitations 
are considered minor or major and how they will affect rating of the individual 
studies will be developed collaboratively with the methodology team.
§Nonrandomized controlled studies refer to intervention studies where 
assignment to intervention and comparison groups is not random (eg, quasi-
experimental study design).
‖Observational studies include prospective and retrospective cohort, case-
control, and cross-sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, 
randomized controlled trials.
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members and their familiarity with the literature in this field, 
the Work Group is confident that a broader review would not 
substantially change our conclusions or recommendations.
The results of the Work Group systematic review are the 10 
lifestyle recommendations (8 dietary and 2 physical activity 
recommendations) (Table 5). Because the Work Group was 
convened to inform the development of clinical guidelines, 
and because most data meeting our criteria for review were 
derived from studies of high-risk populations, these recom-
mendations are directed at patients with CVD risk factors (ie, 
abnormal lipids and/or prehypertension and hypertension). 
The majority of adults in the United States currently have ≥1 of 
these risk factors (33.5% with elevated LDL-C; 27.3%, hyper-
tension; 31%, prehypertension; and 11.3%, diabetes), with 
risk factors increasing with age.6 The Work Group encourages 
heart-healthy nutrition and physical activity behaviors for all 
adults (Section 5.6) (Table 17).
For both BP and lipids, most studies of diet and/or physical 
activity exclude people taking antihypertensive or lipid-lower-
ing medications. Although there is no direct evidence, it is rea-
sonable to expect that the beneficial effects of these lifestyle 
recommendations apply to those taking such medications and 
that following these recommendations can potentially lead to 
better BP and lipid control in those taking medications and/
or reduced medication needs. The recommendations apply to 
adults <80 years of age with and without CVD.
1.2.2. CQ-Based Approach
The Work Group developed an initial set of questions based 
on their expertise and a brief literature review to identify top-
ics of the greatest relevance and impact for the target audi-
ence of the guideline: primary care providers Because of time 
and resource limitations, the Work Group prioritized the 3 
CQs in Table 4.
The body of this report is organized by CQ. For each CQ:
•	 The rationale for its selection is provided, and methods 
are described.
•	 The ESs are presented, which include a rating for qual-
ity, a rationale that supports each item of evidence, and a 
statement. A detailed description of methods is provided in 
the NHLBI Lifestyle Systematic Evidence Review Report 
(http://www.nhlbi.nih.gov/guidelines/cvd_adult/lifestyle/). 
The Full Work Group Report supplement presents docu-
mentation for search strategies and results from the search 
of the published literature.
•	 Recommendations include recommendation strength, 
accompanied by a summary of how the recommenda-
tion derives from the evidence and a discussion of issues 
considered by the Work Group in formulating the recom-
mendation. The ACC/AHA COR/LOE ratings have also 
been added.
The ESs and recommendations are presented by CQ and 
grouped by topic:
•	 CQ1 presents evidence on dietary patterns and macro-
nutrients and their effect on BP and lipids. The dietary 
recommendations for LDL-C lowering are described at 
the end of CQ1.
•	 CQ2 presents the evidence on the effect of dietary sodium 
and potassium intake on BP and CVD outcomes. The 
dietary recommendations for BP lowering are located at 
the end of CQ2.
•	 Finally, CQ3 presents evidence on the effect of physi-
cal activity on lipids and BP and physical activity rec-
ommendations for BP and lipid lowering. The physical 
activity recommendations for BP and lipid lowering are 
located at the end of CQ3.
It should be recognized that formulating recommendations 
derived from evidence reviews in response to CQs has some 
advantages as well as limitations. Because of its desire to 
adhere to the highest quality of evidence, the Work Group 
was restricted to using evidence that met inclusion/exclu-
sion and quality criteria established by the Work Group in 
partnership with the methodologists. When the phrase “there 
is insufficient evidence” is used, the reader must distinguish 
between “insufficient” evidence where no studies meeting 
inclusion/exclusion and quality criteria were found to answer 
a CQ and “insufficient” evidence where RCTs or observa-
tional studies were conducted but the available data do not 
provide sufficient information to formulate a recommenda-
tion. This perspective is important because clinicians could 
see fewer recommendations derived from expert opinion. 
Given this perspective, the clinical and research community 
can identify research questions that need to be answered in 
the future to refine recommendations when updates to the 
guideline are written (Section 6).
1.3. Organization of Work Group
The Work Group was composed of 12 members and 4 ex-offi-
cio members, including physicians and experts in BP, blood 
cholesterol, obesity, and lifestyle management. The authors 
came from the primary care, nursing, pharmacology, nutrition, 
exercise, behavioral science, and epidemiology disciplines 
and also included senior scientific staff from NHLBI and the 
National Institutes of Health.
1.4. Document Reviews and Approval
A formal peer review process initially was completed under 
the auspices of the NHLBI and included 6 expert reviewers 
and representatives of federal agencies. This document was 
Table 4. Critical Questions
Critical Questions:
CQ1. Among adults*, what is the effect of dietary patterns  
and/or macronutrient composition on CVD risk factors, 
when compared with no treatment or with other types of 
interventions?
CQ2. Among adults, what is the effect of dietary intake of sodium 
and potassium on CVD risk factors and outcomes, when 
compared with no treatment or with other types of 
interventions?
CQ3. Among adults, what is the effect of physical activity on  
BP and lipids when compared with no treatment or  
with other types of interventions?
*Those ≥18 years of age and <80 years of age.
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular 
disease.
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Table 5. Summary of Recommendations for Lifestyle Management
Recommendations NHLBI Grade
NHLBI Evidence  
Statements ACC/AHA COR ACC/AHA LOE
DIET
LDL-C: Advise adults who would benefit from LDL-C lowering* to:
1.  Consume a dietary pattern that emphasizes intake of  
 vegetables, fruits, and whole grains; includes low-fat  
dairy products, poultry, fish, legumes, nontropical  
vegetable oils, and nuts; and limits intake of sweets,  
sugar-sweetened beverages, and red meats.
a.  Adapt this dietary pattern to appropriate calorie requirements,  
 personal and cultural food preferences, and nutrition therapy  
for other medical conditions (including diabetes).
b.  Achieve this pattern by following plans such as the DASH dietary  
pattern, the USDA Food Pattern, or the AHA Diet.
A (Strong) CQ1: ES4 (high), ES6 (low),  
ES8 (moderate),  
ES9 (moderate)
I A
2.  Aim for a dietary pattern that achieves 5%–6% of calories from  
saturated fat.
A (Strong) CQ1: ES11 (high) I A
3. Reduce percent of calories from saturated fat. A (Strong) CQ1: ES11 (high),  
ES12 (moderate),  
ES13 (moderate)
I A
4. Reduce percent of calories from trans fat. A (Strong) CQ1: ES14 (moderate),  
ES15 (moderate)
I A
BP: Advise adults who would benefit from BP lowering to:
1.  Consume a dietary pattern that emphasizes intake of vegetables,  
 fruits, and whole grains; includes low-fat dairy products, poultry,  
fish, legumes, nontropical vegetable oils, and nuts; and limits intake  
of sweets, sugar-sweetened beverages, and red meats.
a.  Adapt this dietary pattern to appropriate calorie requirements,  
 personal and cultural food preferences, and nutrition therapy  
for other medical conditions (including diabetes).
b.  Achieve this pattern by following plans such as the DASH  
dietary pattern, the USDA Food Pattern, or the AHA Diet.
A (Strong) CQ1: ES1 (low) ES3 (high),  
ES5 (high), ES6 (low),  
ES7 (low),  
ES8 (moderate)
I A
2. Lower sodium intake. A (Strong) CQ2: ES1 (high),  
ES2 (moderate),  
ES3 (high), ES4 (high),  
ES5 (high), ES8 (low),  
ES9 (low)
I A
3. a. Consume no more than 2400 mg of sodium/d;
b.  Further reduction of sodium intake to 1500 mg/d can  
result in even greater reduction in BP; and
c.  Even without achieving these goals, reducing sodium  
intake by at least 1000 mg/d lowers BP.
B (Moderate) CQ2: ES2 (moderate),  
ES3 (high)
IIa B
4. Combine the DASH dietary pattern with lower sodium intake. A (Strong) CQ1: ES3 (high), ES5 (high), 
ES8 (moderate)
CQ2: ES1 (high),  
ES2 (moderate),  
ES3 (high), ES4 (high),  
ES5 (high), ES6 (moderate)
I A
PHYSICAL ACTIVITY
Lipids
1.  In general, advise adults to engage in aerobic physical activity to  
 reduce LDL-C and non–HDL-C: 3–4 sessions per wk, lasting on  
average 40 min per session, and involving moderate- to  
vigorous-intensity physical activity.
B (Moderate) CQ3: ES1 (moderate), ES2 
(moderate), ES5 (low)
IIa A
BP
1.  In general, advise adults to engage in aerobic physical activity to  
 lower BP: 3–4 sessions per wk, lasting on average 40 min per session,  
and involving moderate- to vigorous-intensity physical activity.
B (Moderate) CQ3: ES1 (high) IIa A
*Refer to 2013 Blood Cholesterol Guideline for guidance on who would benefit from LDL-C lowering.4
ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; COR, Class of Recommendation; CQ, critical question; DASH, 
Dietary Approaches to Stop Hypertension; ES, evidence statement; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOE, Level of 
Evidence; NHLBI, National Heart, Lung, and Blood Institute; and USDA, US Department of Agriculture.
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also reviewed by 4 expert reviewers nominated by the ACC 
and the AHA when the management of the guideline transi-
tioned to the ACC/AHA. The ACC and AHA reviewers’ RWI 
information is published in this document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACC and AHA and endorsed by the 
American Association of Cardiovascular and Pulmonary 
Rehabilitation, American Pharmacists Association, American 
Society for Nutrition, American Society for Preventive 
Cardiology, American Society of Hypertension, Association 
of Black Cardiologists, National Lipid Association, Preventive 
Cardiovascular Nurses Association, and WomenHeart: The 
National Coalition for Women With Heart Disease.
2. Lifestyle Management Recommendations
See Table 5 for the Summary of Lifestyle Recommendations.
3. CQ1—Dietary Patterns and 
Macronutrients: BP and Lipids
See Table 6 for the CQ for BP and lipids with dietary patterns 
and macronutrients.
3.1. Introduction/Rationale
The importance of nutrition in modifying the risk of CVD 
has been repeatedly emphasized.7–11 Historically, the role of 
dietary components has been the predominant focus; however, 
foods are typically consumed in combinations rather than 
individually. Over the past few years, increasing attention has 
been given to dietary patterns and their relationship to health 
outcomes such as CVD.12–20
In intervention studies, specific dietary patterns of defined 
macronutrient composition are identified on the basis of expert 
evidence and a priori hypothesis (eg, the DASH or MED pat-
terns) and then are evaluated in RCTs. In observational stud-
ies, associations between intake and risk factors are assessed. 
Because of resource limitations, CVD morbidity and mortal-
ity outcomes were not included in the evidence review for this 
question. The charge of the Work Group was to inform the 
treatment of lipids and BP; therefore, those risk factors were 
the outcomes of focus.
3.2. Selection of Inclusion/Exclusion Criteria
Work Group members developed eligibility criteria based on 
a Population, Intervention, Comparator, Outcomes, Timing, 
and Setting (PICOTS) approach for screening potential stud-
ies for inclusion in this evidence review. The details of the 
PICOTS approach for CQ1 and Literature Search Yield, 
including summary tables, are available in the Full Work 
Group Report supplement.
3.3. Literature Search Yield
3.3.1. Dietary Pattern/Macronutrient Composition Evidence
In all, 17 studies (28 articles) satisfied the final inclusion crite-
ria and were rated to be of good or fair quality.21–48
The Dietary Pattern Summary Tables (Tables B–1 through 
B–8) are available in the Full Work Group Report supple-
ment. The tables present summary data on the included 
studies organized by dietary pattern/macronutrient composi-
tion or subpopulations of interest, defined by age, sex, race, 
or comorbid condition. Some studies appear in more than 1 
summary table because they address more than 1 correspond-
ing macronutrient composition or dietary pattern comparison.
3.4. CQ1 Evidence Statements
3.4.1. Dietary Patterns
3.4.1.1. MED Pattern
MED pattern description (Table 7): There was no uniform 
definition of the MED diet in the RCTs and cohort studies 
examined. The most common features of diets in these studies 
were that they were higher in fruits (particularly fresh), veg-
etables (emphasizing root and green varieties), whole grains 
(cereals, breads, rice, or pasta), and fatty fish (rich in omega-3 
fatty acids); were lower in red meat (emphasizing lean meats); 
substituted lower-fat or fat-free dairy products for higher-fat 
dairy foods; and used oils (olive or canola), nuts (walnuts, 
almonds, or hazelnuts), or margarines blended with rapeseed 
or flaxseed oils in lieu of butter and other fats. The MED pat-
terns examined tended to be moderate in total fat (32% to 35% 
of total calories), relatively low in saturated fat (9% to 10% of 
total calories), high in fiber (27 to 37 g/d), and high in polyun-
saturated fatty acids (particularly omega-3s).
3.4.1.2. DASH Dietary Pattern
DASH dietary pattern description (Table 8): The DASH 
dietary pattern is high in vegetables, fruits, low-fat dairy prod-
ucts, whole grains, poultry, fish, and nuts and is low in sweets, 
Table 6. CQ for Dietary Patterns and Macronutrients: BP and 
Lipids
CQ1:
Among adults, what is the effect of dietary patterns and/or macronutrient 
composition on CVD risk factors, when compared with no treatment or  
with other types of interventions?
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular disease.
Table 7. ESs for BP and Lipids With the MED Pattern
BP
ES1.
•	Counseling to eat a MED pattern, as compared with minimal advice  
 to consume a low-fat dietary pattern, in free-living middle-aged or  
older adults (with type 2 diabetes or at least 3 CVD risk factors)  
reduced BP by 6–7/2–3 mm Hg. In an observational study of healthy 
younger adults, adherence to a MED pattern was associated with  
lower BP (2–3/1–2 mm Hg).
Strength of Evidence: Low
Lipids
ES2.
•	Counseling to eat a MED pattern, compared with minimal or  
 no dietary advice, in free-living middle-aged or older adults  
(with or without CVD or at high risk for CVD) resulted in no consistent 
effect on plasma LDL-C, HDL-C, and triglycerides, in part because of 
substantial differences and limitations in the studies.
Strength of Evidence: Low
BP indicates blood pressure; CVD, cardiovascular disease; ES, evidence 
statement; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; and MED, Mediterranean-style dietary pattern.
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
S84  Circulation  June 24, 2014
sugar-sweetened beverages, and red meats. The DASH dietary 
pattern is low in saturated fat, total fat, and cholesterol. It is rich in 
potassium, magnesium, and calcium, as well as protein and fiber.
3.4.1.3. DASH Variations
DASH variations description (Table 9): In OmniHeart 
(Optimal Macronutrient Intake Trial for Heart Health), 2 varia-
tions of the DASH dietary pattern were compared with DASH: 
one that replaced 10% of total daily energy from carbohydrate 
with protein, and another that replaced the same amount of car-
bohydrate with unsaturated fat. These patterns were studied in 
an adequately powered crossover trial of 164 adults in which 
the participants were given all of their daily food.
3.4.2. Dietary Fat and Cholesterol
See Table 10 for ESs for saturated fat, trans fat, and dietary 
cholesterol.
3.5. Diet Recommendations for LDL-C Lowering*
The following diet recommendations for LDL-C lowering are 
based on the ESs from CQ1 on dietary patterns and fatty acids. 
Diet recommendations for BP lowering are based on CQ1 and 
CQ2 and are located after the CQ2 ESs. The physical activity 
and lipids ESs and recommendations are located in CQ3.
1. Advise adults who would benefit from LDL-C 
lowering to:
•	 Consume a dietary pattern that emphasizes intake 
of vegetables, fruits, and whole grains; includes 
low-fat dairy products, poultry, fish, legumes, non-
tropical vegetable oils, and nuts; and limits intake of 
sweets, sugar-sweetened beverages, and red meats.
○ Adapt this dietary pattern to appropriate calo-
rie requirements, personal and cultural food 
preferences, and nutrition therapy for other 
medical conditions (including diabetes).
○ Achieve this pattern by following plans such as 
the DASH dietary pattern, the US Department 
of Agriculture (USDA) Food Pattern, or the 
AHA Diet.
NHLBI Grade: A (Strong); ACC/AHA COR: I, LOE: A
Rationale: This recommendation is based largely on studies 
of the DASH dietary pattern (DASH and DASH-Sodium), 
which provided the highest-quality evidence for a dietary pat-
tern causing improvements in BP and lipid profiles (Tables 8 
and 9). The LDL-C–lowering effect has been demonstrated 
in men and women, African Americans and non–African 
Americans, and in adults of all ages (Table 8, ES6). The evi-
dence suggests that the effects of the recommended dietary 
pattern persist as long as the pattern is consumed.
The caloric (energy) intake should be appropriate for the indi-
vidual (eg, restricted for those attempting weight loss). Patients 
should also be encouraged to adapt the recommended dietary pat-
tern to their personal and cultural preferences. Materials are avail-
able to assist patients in achieving the recommended dietary pattern 
at different calorie levels (Table 9). The 2010 US Department of 
Health and Human Services Dietary Guidelines for Americans 
recommend the USDA Food Pattern and the DASH dietary pat-
tern.49 Overall, the recommended dietary pattern is consistent 
with the AHA Diet50 and the USDA Food Pattern.49 The USDA 
Food Pattern offers lacto-ovo vegetarian and vegan adaptations. 
Therefore, this recommendation is consistent with other national 
guidelines. Clinicians should be familiar with the recommenda-
tions, advise their patients to adopt them, and provide easy access 
to information (Table 11). Dietary planning and nutritional coun-
seling are often facilitated by referral to a nutrition professional.
2. Advise adults who would benefit from LDL-C 
lowering to:
•	 Aim for a dietary pattern that achieves 5% to 6% 
of calories from saturated fat.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: As described in Table 10, ES11 there is strong evi-
dence that reductions in LDL-C were achieved when dietary 
Table 8. ESs for BP and Lipids With the DASH Pattern
BP
ES3.
•	When all food was supplied to adults with BP 120–159/80–95 mm Hg  
 and both body weight and sodium intake were kept stable, the DASH 
dietary pattern, compared with a typical American diet of the 1990s, 
lowered BP by 5–6/3 mm Hg.
Strength of Evidence: High
Lipids
ES4.
•	When food was supplied to adults with a total cholesterol level  
 <260 mg/dL and LDL-C level <160 mg/dL and body weight was  
kept stable, the DASH dietary pattern, compared with a typical  
American diet of the 1990s, lowered LDL-C by 11 mg/dL, lowered  
HDL-C by 4 mg/dL, and had no effect on triglycerides.
Strength of Evidence: High
DASH DIETARY PATTERN SUBPOPULATIONS
Subpopulations and BP
ES5.
•	When all food was supplied to adults with BP 120–159/80–95 mm Hg  
 and body weight was kept stable, the DASH dietary pattern, compared 
with the typical American diet of the 1990s, lowered BP in women and 
men, African-American and non–African-American adults, older and 
younger adults, and hypertensive and nonhypertensive adults.
Strength of Evidence: High
Subpopulations and Lipids
ES6.
•	When all food was supplied to adults with a total cholesterol level  
 <260 mg/dL and LDL-C level <160 mg/dL and body weight was  
kept stable, the DASH dietary pattern, compared with a typical  
American diet of the 1990s, lowered LDL-C similarly in subgroups: 
African-American and non–African-American adults and hypertensive and 
nonhypertensive adults.
Strength of Evidence: Low
ES7.
•	When all food was supplied to adults with a total cholesterol level  
 <260 mg/dL and LDL-C level <160 mg/dL and body weight was  
kept stable, the DASH dietary pattern, compared with a typical  
American diet of the 1990s, lowered HDL-C similarly in subgroups: 
African-American and non–African-American adults, hypertensive  
and nonhypertensive adults, and men and women.
Strength of Evidence: Low
BP indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension; 
ES, evidence statement; HDL-C, high-density lipoprotein cholesterol.
*Refer to the 2013 Blood Cholesterol Guideline4 for guidance on who 
would benefit from LDL-C lowering.
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patterns were followed in which saturated fat intake was 
reduced from 14% to 15% of calories to 5% to 6%. As previ-
ously noted, these studies did not isolate the effect of saturated 
fat on LDL-C lowering. Intake of saturated fat has decreased 
in the United States over the past few decades and is currently 
estimated at 11% of energy in the US population ≥2 years 
of age.51 However, this level of saturated fat intake is higher 
than that tested in the DASH and DELTA (Dietary Effects on 
Lipoproteins and Thrombogenic Activity) trials (5% to 6%) 
and is not consistent with consuming a diet rich in vegeta-
bles, fruits, low-fat dairy products, whole grains, poultry, fish, 
legumes and nuts, and vegetable oils and limited in sweets, 
sugar-sweetened beverages, and red meat. Given the current 
average intake of saturated fat at 11% of calories, it would be 
beneficial for those who would benefit from LDL-C lowering 
to decrease saturated fat intake to 5% to 6% of calories.
3. Advise adults who would benefit from LDL-C 
lowering to:
•	 Reduce percentage of calories from saturated fat.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Reducing saturated fat intake lowers both LDL-C 
and HDL-C. Because the absolute effect tends to be greater for 
LDL-C than HDL-C, reducing saturated fat intake has a ben-
eficial effect on the lipid profile. Given that reducing saturated 
fat intake lowers LDL-C regardless of whether the saturated 
fat is replaced by carbohydrate, monounsaturated fatty acids, 
or polyunsaturated fatty acids, the Work Group does not 
specify which of these 3 macronutrients should be substituted 
in place of saturated fat. However, favorable effects on lipid 
profiles are greater when saturated fat is replaced by poly-
unsaturated fatty acids, followed by monounsaturated fatty 
acids, and then carbohydrates. It is important to note that there 
are various types and degrees of refinement of carbohydrates. 
Substitution of saturated fat with whole grains is preferable 
to refined carbohydrates. For American adults who eat more 
saturated fat than the current average, some reduction is war-
ranted, and adhering to a “heart-healthy” dietary pattern from 
dietary recommendation No. 1 for LDL-C lowering will likely 
result in a reduction of saturated fat.
4. Advise adults who would benefit from LDL-C 
lowering to:
•	 Reduce percentage of calories from trans fat.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Reducing intake of trans fatty acids lowers LDL-
C, with little or no effect on HDL-C or triglycerides levels. 
The direction of the relationship between trans fatty acids 
and LDL-C is consistent, regardless of whether the trans 
fatty acids are replaced by carbohydrates, monounsaturated 
fatty acids, or polyunsaturated fatty acids. Using 2003 to 
2006 NHANES (National Health and Nutrition Examination 
Survey) data, intake of trans fat from partially hydrogenated 
oils was estimated at a mean of 1.3 g/d to 1.6 g/d among the 
US population ≥2 years of age.52 Although the intake level 
appears low, certain subgroups within the US population 
may still be consuming relatively high levels of trans fatty 
acids. For this reason, the Work Group recommends that 
emphasis continue to be placed on the reduction of trans fat 
in the diet. Even if intake of trans fat from partially hydroge-
nated oils decreases, naturally occurring trans fatty acids in 
the form of ruminant fat from meat and dairy products may 
still be present in small amounts in the US diet. Adhering to 
the recommendation to reduce dietary sources of saturated 
fat (meat and dairy fat) will result in additional reductions 
in trans fat intake.
4. CQ2—Sodium and Potassium: 
BP and CVD Outcomes
See Table 12 for the CQ on BP and CVD outcomes with 
sodium and potassium.
4.1. Introduction and Rationale
Vitamins and minerals typically are consumed in foods. 
However, it is sometimes possible to isolate the effect of indi-
vidual minerals to determine the effects on health outcomes. 
Therefore, the Work Group decided that a systematic review 
was warranted to determine the individual effects of the min-
erals sodium and potassium, which are associated with CVD 
risk factors and outcomes. Other minerals, such as calcium 
and magnesium, were also considered but were not included 
in the systematic review because their consumption is lim-
ited to relatively few specific foods or food groups (eg, cal-
cium and dairy products); furthermore, it was unlikely that a 
Table 9. ESs for DASH Variations/Glycemic Index/Load  
Dietary Approaches
BP
ES8.
•	In adults with BP of 120–159/80–95 mm Hg, modifying the DASH  
 dietary pattern by replacing 10% of calories from carbohydrates  
with the same amount of either protein or unsaturated fat (8% 
monounsaturated and 2% polyunsaturated) lowered systolic BP by 
1 mm Hg compared with the DASH dietary pattern. Among adults with  
BP 140–159/90–95 mm Hg, these replacements lowered systolic BP  
by 3 mm Hg relative to DASH.
Strength of Evidence: Moderate
Lipids
ES9.
•	In adults with average baseline LDL-C level of 130 mg/dL, HDL-C level  
 of 50 mg/dL, and triglyceride level of 100 mg/dL, modifying the DASH 
dietary pattern by replacing 10% of calories from carbohydrates with 10% 
of calories from protein lowered LDL-C by 3 mg/dL, HDL-C by 1 mg/dL, 
and triglycerides by 16 mg/dL compared with the DASH dietary pattern. 
Replacing 10% of calories from carbohydrates with 10% of calories from 
unsaturated fat (8% monounsaturated and 2% polyunsaturated) lowered 
LDL-C similarly, increased HDL-C by 1 mg/dL,  
and lowered triglycerides by 10 mg/dL as compared with the DASH 
dietary pattern.
Strength of Evidence: Moderate
ES10.
•	There is insufficient evidence to determine whether low-glycemic  
 diets versus high-glycemic diets affect lipids or BP for adults without 
diabetes. The evidence for this relationship in adults with diabetes  
was not reviewed.
Strength of Evidence: Insufficient
BP indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension; 
ES, evidence statement; HDL-C, high-density lipoprotein cholesterol; and LDL-C, 
low-density lipoprotein cholesterol. by guest on A
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recommendation to increase or decrease consumption of the 
mineral rather than the food could be implemented.
In contrast, sodium was reviewed as a single nutrient 
because little sodium is found naturally in food, and it is added 
to foods primarily during preparation, at preservation, and/or 
at the time of consumption. Therefore, it is theoretically pos-
sible to alter sodium intake without altering intake of specific 
foods or overall dietary pattern. In addition, potassium was 
reviewed as a single nutrient because it has been hypothesized 
that dietary potassium intake may lower BP independent of 
other nutrients or foods. In addition, the effect of sodium on 
BP may be modulated by concomitant potassium intake.
Most of the clinical trial evidence pertains to effects of 
minerals on risk factors (ie, BP and plasma lipids) that are 
relevant, intermediate outcomes for CVD. In addition, data 
primarily from observational studies provide evidence on the 
effects of dietary sodium and potassium on outcomes that are 
CVD events.
4.2. Selection of Inclusion/Exclusion Criteria
Work Group members developed eligibility criteria on the 
basis of a PICOTS approach for screening potential studies for 
inclusion in the evidence review. The PICOTS approach for 
CQ2 and other detailed methods are in the NHLBI Lifestyle 
Systematic Evidence Review report.
CQ2 was established to examine studies that assessed the 
impact of sodium and potassium on BP and cardiovascular 
morbidity and mortality. The studies included adults with or 
without established CVD; with or without CVD risk factors; 
with or without tobacco use; and who were of normal weight, 
overweight, or obese. In addition, intervention sample sizes 
were required to be at least 50 for biomarker and risk factor 
Table 10. ESs for Dietary Fat and Cholesterol
Saturated Fat
ES11.
•	When food was supplied to adults in a dietary pattern that achieved a macronutrient composition of 5%–6% saturated fat, 26%–27% total fat,  
 15%–18% protein, and 55%–59% carbohydrate compared with the control diet (14%–15% saturated fat, 34%–38% total fat, 13%–15% protein,  
and 48%–51% carbohydrate), LDL-C was lowered 11–13 mg/dL in 2 studies and 11% in another study.
Strength of Evidence: High
ES12.
•	In controlled feeding trials among adults, for every 1% of energy from SFA that is replaced by 1% of energy from carbohydrate, MUFA, or PUFA:
– LDL-C is lowered by an estimated 1.2, 1.3, and 1.8 mg/dL, respectively.
– HDL-C is lowered by an estimated 0.4, 1.2, and 0.2 mg/dL, respectively.
•	For every 1% of energy from SFA that is replaced by 1% of energy from:
– Carbohydrate and MUFA:
○ Triglycerides are raised by an estimated 1.9 and 0.2 mg/dL, respectively.
– PUFA:
○ Triglycerides are lowered by an estimated 0.4 mg/dL.
Strength of Evidence: Moderate
ES13.
•	In controlled feeding trials among adults, for every 1% of energy from carbohydrate that is replaced by 1% of energy from:
– MUFA:
○ LDL-C is lowered by 0.3 mg/dL, HDL-C is raised by 0.3 mg/dL, and triglycerides are lowered by 1.7 mg/dL.
– PUFA:
○ LDL-C is lowered by 0.7 mg/dL, HDL-C is raised by 0.2 mg/dL, and triglycerides are lowered by 2.3 mg/dL.
Strength of Evidence: Moderate
Trans Fat
ES14.
•	In controlled feeding trials among adults, for every 1% of energy from trans monounsaturated fatty acids replaced with 1% of energy from:
– MUFA or PUFA
○ LDL-C is lowered by 1.5 mg/dL and 2.0 mg/dL, respectively.
– SFA, MUFA, or PUFA:
○ HDL-C is increased by an estimated 0.5, 0.4, and 0.5 mg/dL, respectively.
– MUFA or PUFA:
○ Triglycerides are decreased by an estimated 1.2 and 1.3 mg/dL.
Strength of Evidence: Moderate
ES15.
•	In controlled feeding trials among adults, the replacement of 1% of energy as trans monounsaturated fatty acids with carbohydrate decreased LDL-C levels by  
1.5 mg/dL and had no effect on HDL-C cholesterol and triglyceride levels.
Strength of Evidence: Moderate
Dietary Cholesterol
ES16.
•	There is insufficient evidence to determine whether lowering dietary cholesterol reduces LDL-C.
Strength of Evidence: Insufficient
ES indicates evidence statement; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; and SFA, saturated fatty acid.
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studies and 500 for cardiovascular morbidity and mortality. 
Because a separate Obesity Expert Panel reviewed evidence 
on the effect of weight loss on CVD risk factors and out-
comes, the Work Group excluded studies in which weight 
change was >3%.
4.3. Literature Search Yield
In all, 34 studies (46 citations) satisfied the CQ2 inclusion cri-
teria and were rated as good or fair quality.31,32,46,47,53–94
The CQ2 summary tables are available in the Full Work 
Group Report supplement. The tables present data on the stud-
ies used in the evidence review organized by mineral (sodium 
or potassium), outcomes (BP or CVD outcomes), sodium 
subquestions (overall results, different levels of sodium, 
sodium and other dietary changes), and subpopulations (sex, 
Summary Table C–4a; race/ethnicity, Summary Table C–4b; 
age, Summary Table C–4c; and hypertension status, Summary 
Table C–4d). Some studies appear in more than 1 summary 
table because they address more than 1 corresponding mineral 
or subquestion.
4.4. CQ2 Evidence Statements
See Table 13 for the CQ2 ESs for sodium and BP.
4.4.1. Sodium and BP
A note about the unit of measure presented for dietary and 
urinary sodium: sodium is presented in studies in millimoles 
(mmol), grams (g), and milligrams (mg). The Work Group 
chose to convert the sodium results to milligrams for the 
ESs, recommendations, and rationales so that data from dif-
ferent studies would be displayed in a consistent unit. Also, 
US dietary recommendations and the Nutrition Facts labels 
on food products display sodium in milligrams, and this unit 
(mg) will be easier for healthcare providers to communicate 
with patients. Urinary and dietary sodium are portrayed in the 
original units from each published study in the CQ2 summary 
tables (C–1 to C–8).
4.5. Diet Recommendations for BP Lowering
1. Advise adults who would benefit from BP lowering to:
 a. Consume a dietary pattern that emphasizes intake 
of vegetables, fruits, and whole grains; includes 
low-fat dairy products, poultry, fish, legumes, 
nontropical vegetable oils, and nuts; and limits 
intake of sweets, sugar-sweetened beverages, and 
red meats.
i. Adapt this dietary pattern to appropriate calo-
rie requirements, personal and cultural food 
preferences, and nutrition therapy for other 
medical conditions (including diabetes).
ii. Achieve this pattern by following plans such 
as the DASH dietary pattern, the USDA Food 
Pattern, or the AHA Diet.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: This recommendation is based largely on studies 
of the DASH dietary pattern (DASH and DASH-Sodium), 
which provided the highest-quality evidence that this food-
based dietary pattern improves lipid profiles and BP (Tables 
8 and 9, CQ1 ES3–ES9). This evidence was supplemented 
by studies of low quality in which various adaptations of the 
MED pattern were tested and also found to reduce BP (Table 
7, CQ1 ES1). The evidence suggests that the effects of the 
recommended dietary pattern persist as long as the pattern is 
consumed. The BP-lowering effect has been demonstrated in 
adults with hypertension and prehypertension and is evident 
in men and women, African-American and non–African-
American adults, and older and younger adults (Table 8, ES5). 
The dietary pattern's effect on BP is independent of changes 
in weight and sodium intake. The magnitude of effect is suf-
ficient to prevent progression from prehypertension to hyper-
tension, promote nonpharmacological BP control in those with 
hypertension, and supplement pharmacological BP lowering.
The caloric (energy) intake should be appropriate for the 
individual (eg, restricted for those attempting weight loss). 
Patients should also be encouraged to adapt the recommended 
dietary pattern to their personal and cultural preferences. 
Materials are available to assist patients in achieving the recom-
mended dietary pattern at different calorie levels (Table 9). The 
2010 US Department of Health and Human Services Dietary 
Guidelines for Americans recommend the USDA Food Pattern 
and the DASH dietary pattern.49 Overall, the recommended 
dietary pattern is consistent with the AHA Diet50 and the USDA 
Food Pattern.49 The USDA Food Pattern offers lacto-ovo veg-
etarian and vegan adaptations. Therefore, this recommendation 
is consistent with other national guidelines. Clinicians should 
be familiar with the recommendations, advise their patients to 
adopt them, and provide easy access to information (Table 11). 
Table 11. Resources and Information for Dietary Planning
DASH Eating Plan
•	Your Guide to Lowering Your Blood Pressure With DASH  
 (http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf)
•	Your Guide to Lowering Your Blood Pressure With DASH Brochure  
 (http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/dash_brief.pdf)
AHA Diet and Lifestyle Recommendations
•	AHA Diet and Lifestyle Recommendations Article  
  (http://www.heart.org/HEARTORG/GettingHealthy/Diet-and-Lifestyle-
Recommendations_UCM_305855_Article.jsp)
•	AHA Diet and Lifestyle Recommendations 2006 Scientific Statement  
 (http://circ.ahajournals.org/content/114/1/82.full.pdf)11
Dietary Guidelines for Americans
•	2010 Dietary Guidelines for Americans  
 (http://www.cnpp.usda.gov/DGAs2010-PolicyDocument.htm)49
•	2011 Dietary Guidelines for Americans Brochure  
 (http://www.cnpp.usda.gov/Publications/MyPlate/DG2010Brochure.pdf)
•	USDA Food Patterns  
  (http://www.cnpp.usda.gov/Publications/USDAFoodPatterns/
USDAFoodPatternsSummaryTable.pdf)
AHA indicates American Heart Association; DASH, Dietary Approaches to Stop 
Hypertension; and USDA, US Department of Agriculture.
Table 12. CQ for Sodium and Potassium:  
BP and CVD Outcomes
CQ2:
Among adults, what is the effect of dietary intake of sodium and potassium  
  on CVD risk factors and outcomes, when compared with no treatment or with 
other types of interventions?
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular disease.
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Table 13. CQ2 ESs for Sodium and BP
Overall Results of Sodium and the Effect on BP:
What Is the Overall Effect of Dietary Intake of Sodium on BP?
ES1.
•	In adults 25 to 80 years of age with BP 120–159/80–95 mm Hg, reducing sodium intake lowers BP.
Strength of Evidence: High
Comparison of Different Levels of Sodium Intake:
What Is the Effect of Different Levels of Dietary Sodium Intake on BP?
ES2.
•	In adults 25 to 75 years of age with BP 120–159/80–95 mm Hg, a reduction in sodium intake that achieves a mean 24-h urinary sodium excretion of  
 approximately 2400 mg/d, relative to approximately 3300 mg/d, lowers BP by 2/1 mm Hg. A reduction in sodium intake that achieves a mean 24-h  
urinary sodium excretion of approximately 1500 mg/d lowers BP by 7/3 mm Hg.
Strength of Evidence: Moderate
ES3.
•	In adults 30–80 years of age with or without hypertension, counseling to reduce sodium intake by an average of 1150 mg/d reduces BP by 3–4/1–2 mm Hg.
Strength of Evidence: High
Sodium in Subpopulations:
What Is the Effect of Sodium on BP in Subgroups Defined by Sex, Race/Ethnicity, Age, and Hypertension Status?
ES4.
•	In adults with prehypertension or hypertension, reducing sodium intake lowers BP in women and men, African-American and non–African-American adults,  
and older and younger adults.
Strength of Evidence: High
ES5.
•	Reducing sodium intake lowers BP in adults with either prehypertension or hypertension who are eating either the typical American diet or the DASH  
dietary pattern. The effect is greater in those with hypertension.
Strength of Evidence: High
Sodium and Dietary Pattern Changes:
What Is the Effect of Sodium on BP in the Context of Dietary Pattern Changes?
ES6.
•	In adults 22–80 years of age with BP 120–159/80–95 mm Hg, the combination of reduced sodium intake plus eating the DASH dietary pattern lowers  
BP more than reduced sodium intake alone.
Strength of Evidence: Moderate
Sodium in the Context of Other Minerals and BP:
What Is the Effect of Sodium on BP in the Context of Other Single Minerals?
ES7.
•	There is insufficient evidence from RCTs to determine whether reducing sodium intake plus changing dietary intake of any other single mineral  
(eg, increasing potassium, calcium, or magnesium) lowers BP more than reducing sodium intake alone.
Strength of Evidence: Insufficient
Sodium and Congestive Heart Disease/CVD Outcomes:
What Is the Effect of Dietary Intake of Sodium on CVD Outcomes?
ES8.
•	A reduction in sodium intake of approximately 1000 mg/d reduces CVD events by about 30%.
Strength of Evidence: Low
ES9.
•	Higher dietary sodium intake is associated with a greater risk of fatal and nonfatal stroke and CVD.
Strength of Evidence: Low
ES10.
•	There is insufficient evidence to determine the association between sodium intake and the development of HF.
Strength of Evidence: Insufficient
ES11.
•	There is insufficient evidence to assess the effect of reducing dietary sodium intake on cardiovascular outcomes in patients with existing HF.
Strength of Evidence: Insufficient
Potassium and BP and Congestive Heart Disease/CVD Outcomes:
What Is the Effect of Dietary Intake of Potassium on BP and CVD Outcomes?
ES12.
•	There is insufficient evidence to determine whether increasing dietary potassium intake lowers BP.
Strength of Evidence: Insufficient
ES13.
•	In observational studies with appropriate adjustments (eg, BP, sodium intake), higher dietary potassium intake is associated with lower stroke risk.
Strength of Evidence: Low
ES14.
•	There is insufficient evidence to determine whether there is an association between dietary potassium intake and congestive heart disease, HF,  
or cardiovascular mortality rate.
Strength of Evidence: Insufficient
BP indicates blood pressure; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; ES, evidence statement; HF, heart failure; and RCT, 
randomized controlled trial.
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Dietary planning and nutritional counseling are often facili-
tated by referral to a nutrition professional.
2. Advise adults who would benefit from BP lowering to:
a. Lower sodium intake
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: There is strong and consistent clinical trial evidence 
that reducing sodium intake lowers BP. This BP-lowering 
effect has been demonstrated in adults with hypertension and 
prehypertension, in men and women, in African-American 
and non–African-American adults, and in older and younger 
adults. Trials contributing to this evidence include well-con-
trolled feeding studies as well as studies in which participants 
were counseled to lower sodium intake. The effect of reduc-
ing sodium intake on BP is independent of changes in weight. 
The magnitude of effect is sufficient both to prevent progres-
sion from prehypertension to hypertension and to promote 
nonpharmacological BP control in those with hypertension. 
Observational data also suggest that lower sodium intake is 
associated with lower risk of cardiovascular events in people 
with and without hypertension, which is hypothesized to 
occur through reductions in BP.
3. Advise adults who would benefit from BP lowering 
to:
a. Consume no more than 2400 mg of sodium/d;
b. Further reduction of sodium intake to 1500 mg/d 
can result in even greater reduction in BP;
c. Even without achieving these goals, reducing 
sodium intake by at least 1000 mg/d lowers BP.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: B
Rationale: One well-conducted trial demonstrated clinically 
meaningful lowering of BP when sodium was reduced to 
2400 mg/d, with lower BPs achieved when sodium intake was 
reduced to 1500 mg/d. Reductions of 1000 mg/d were shown 
to be beneficial in trials, and observational studies estimated 
significant reductions in relative risk associated with changes 
in sodium intake of about 1000 mg/d. This recommendation 
is directed at the two thirds of the US adults who have prehy-
pertension or hypertension, for whom reducing sodium intake 
can prevent or improve control of hypertension and poten-
tially reduce cardiovascular events.
The Work Group acknowledges that the recommenda-
tion to reduce sodium intake to ≤2400 mg/d differs slightly 
from other current dietary recommendations—specifically, 
the 2010 Dietary Guidelines for Americans and the Institute 
of Medicine Dietary Reference Intakes; both of these publi-
cations recommend 2300 mg/d as the upper limit of intake 
for adults. Although the impact on behavior of a difference 
between intakes of 2400 mg of sodium/d versus 2300 mg 
of sodium/d would be minimal, these recommendations are 
based on the strongest clinical trial evidence available: the 
achieved level of 2400 mg/d from the DASH-Sodium trial 
(estimated from average urinary sodium excretion) (Table 
11, CQ2 ES2).
The strength of this recommendation is graded “moder-
ate” because fewer clinical trials were used to devise the 
2400-mg and 1500-mg goals than the large number of tri-
als used to inform the overall recommendation on sodium 
(dietary recommendation No. 2 for BP lowering), which is 
graded “strong.”
Reducing sodium intake can be challenging for an indi-
vidual because of the ubiquitous nature of sodium in the 
American food supply. Educational materials with strategies 
to help patients lower sodium intake are provided by several 
federal and private sources.49,95–98 Ultimately, however, signifi-
cant changes in sodium intake among US adults may require 
changes both in individual behavior and in food manufactur-
ing and processing.
4. Advise adults who would benefit from BP lowering to:
a.  Combine the DASH dietary pattern with lower 
sodium intake.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Both a healthy dietary pattern, as exemplified by 
DASH, and reduced sodium intake independently reduce BP. 
However, the BP-lowering effect is even greater when these 
dietary changes are combined. In the 60% of US adults with 
prehypertension or hypertension, simultaneously implement-
ing dietary recommendations No. 1 and No. 2 for BP lowering 
can prevent and control hypertension more than either inter-
vention alone.
5. CQ3—Physical Activity: Lipids and BP
See Table 14 for the CQ for physical activity and lipids and 
BP.
5.1. Introduction/Rationale
Large bodies of observational data show an association 
between higher levels of physical activity and lower rates of 
many chronic diseases, including CVD, and enhanced longev-
ity.99–101 Furthermore, an inverse dose-response relation exists, 
with increasing higher levels of activity associated with com-
mensurately lower rates of CVD in a curvilinear fashion.102,103 
In a recent analysis, it was estimated that by eliminating phys-
ical inactivity, 6% of coronary heart disease worldwide may 
be eliminated, and life expectancy of the world population 
may be increased by 0.68 years.104,105
Among the mechanisms proposed to mediate the relation-
ship between physical activity and decreased CVD rates are 
beneficial effects of exercise on lipid profile and BP.106 In one 
study, it was estimated that the beneficial effects of physical 
activity on BP and development of hypertension explained 
some 27% of the activity-related reduction in observed CVD 
rates, while 19% and 16% of the reduction in CVD rates could 
be explained by the beneficial effects of physical activity on 
traditional lipids and novel lipids, respectively.
In the remainder of Section 5, the Work Group elaborates 
on findings from meta-analyses of the effects of physical 
activity on changes in lipid profile and BP.
5.2. Selection of Inclusion/Exclusion Criteria
Because of resource limitations, the Work Group included 
only systematic reviews and meta-analyses of RCTs or 
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controlled clinical trials published from 2001 through 2011. 
Detailed inclusion/exclusion criteria are available in the Full 
Work Group Report supplement.
5.3. Literature Search Yield
A total of 26 systematic reviews and meta-analyses were iden-
tified that met inclusion/exclusion criteria and were rated as 
good or fair quality.105,107–130
The CQ3 subcommittee members next identified the 
included systematic reviews and meta-analyses that contained 
detailed data on BP outcomes. They identified 11 studies with 
data on BP outcomes. Ten meta-analyses and 1 systematic 
review examined the effects of aerobic exercise. One system-
atic review looked at the effects of resistance training. The CQ3 
subcommittee members next identified the included systematic 
reviews and meta-analyses that contained detailed data on lipid 
outcomes. They identified 14 studies with data on lipid out-
comes, including 10 meta-analyses and 4 systematic reviews.
The next step in the evidence review process for systematic 
reviews and meta-analyses was to develop ESs and recom-
mendations from the included studies and present them to the 
full Work Group for consideration and voting. Because each 
of these systematic reviews and meta-analyses summarizes 
evidence from several studies, NHLBI staff and Work Group 
members determined that the development of formal evidence 
tables and summary tables of individual articles was unneces-
sary. CQ3 subcommittee members developed evidence tables 
that are available in the Full Work Group Report supplement 
(CQ3 Summary Tables: Summary Table D–1: Aerobic Exercise 
and LDL-C, Summary Table D–2: Resistance Exercise and 
LDL-C, Summary Table D–3: Aerobic Exercise and HDL-C, 
and Summary Table D–4: Resistance Exercise and HDL-C) to 
summarize the evidence on physical activity and lipids.
5.4. CQ3 Evidence Statements
5.4.1. Physical Activity and Lipids
See Table 15 for the CQ3 ESs for physical activity and lipids.
This section examines evidence supporting the use of phys-
ical activity alone (ie, not in combination with other interven-
tions, such as dietary interventions or weight loss) versus no 
physical activity or other type of intervention for improve-
ments in selected blood lipids (HDL-C, LDL-C, triglycerides, 
and non–HDL-C). The 2008 Physical Activity Guidelines 
Advisory Committee Report was used as the starting point for 
evidence review.99 Additionally, a systematic search identified 
8 meta-analyses from 2001 onward and 5 systematic reviews 
rated fair to good that addressed this question and were 
included as the evidence base.
5.4.2. Physical Activity and BP
This section examines evidence supporting the use of physical 
activity alone (ie, not in combination with other interventions, 
such as dietary interventions or weight loss) versus no physi-
cal activity or other types of intervention for BP reduction. 
The 2008 Physical Activity Guidelines Advisory Committee 
Report was used as the starting point for evidence review.99 
Additionally, a systematic search identified 15 meta-anal-
yses from 2001 onward and reviews rated fair to good that 
addressed this question. Details of the search are provided in 
the Full Work Group Report supplement.
5.4.2.1. Aerobic Exercise Training and BP
See Table 16 for the ES for aerobic exercise training and BP.
5.4.2.2. Resistance Exercise Training and BP
The 2008 Physical Activity Guidelines Advisory Committee 
focused on data from a meta-analysis of 9 RCTs of resistance 
training that included 341 subjects.131 However, given the 
limited parameters of the systematic search described previ-
ously for CQ3 (Section 5.3), only 1 review was identified. A 
Table 15. ESs for Physical Activity and Lipids
Aerobic Exercise Training and Lipids
ES1.
•	Among adults, aerobic physical activity, compared with control  
interventions, reduces LDL-C 3–6 mg/dL on average.
Strength of Evidence: Moderate
ES2.
•	Among adults, aerobic physical activity alone, compared with control  
interventions, reduces non–HDL-C 6 mg/dL on average.
Strength of Evidence: Moderate
ES3.
•	Among adults, aerobic physical activity alone, compared with control  
interventions, has no consistent effect on triglycerides.
Strength of Evidence: Moderate
ES4.
•	Among adults, aerobic physical activity alone, compared with  
control interventions, has no consistent effect on HDL-C.
Strength of Evidence: Moderate
Resistance Exercise Training and Lipids
ES5.
•	Among adults, resistance training, compared with control interventions,  
 reduces LDL-C, triglycerides, and non–HDL-C by 6–9 mg/dL on average 
and has no effect on HDL-C. Typical interventions shown to reduce  
LDL-C, triglycerides, and non–HDL-C and to have no effect on HDL-C 
include resistance physical activity programs that average 24 wk duration 
and include ≥3 d/wk, with 9 exercises performed for 3 sets and 11 
repetitions at an average intensity of 70% of 1 maximal repetition.
Strength of Evidence: Low
ES indicates evidence statement; HDL-C, high-density lipoprotein cholesterol; 
and LDL-C, low-density lipoprotein cholesterol.
Table 16. ES for Aerobic Exercise Training and BP
ES1.
•	Among adult men and women at all BP levels, including individuals  
 with hypertension, aerobic physical activity decreases systolic and 
diastolic BP, on average by 2–5 mm Hg and 1–4 mm Hg, respectively. 
Typical interventions shown to be effective for lowering BP include 
aerobic physical activity of, on average, at least 12 wk duration, with 
3–4 sessions per wk, lasting on average 40 min/session and involving 
moderate- to vigorous-intensity physical activity.
Strength of Evidence: High
BP indicates blood pressure; and ES, evidence statement.
Table 14. CQ for Physical Activity: Lipids and BP
CQ3:
Among adults, what is the effect of physical activity on BP and lipids  
 when compared with no treatment or with other types of interventions?
BP indicates blood pressure; and CQ, critical question.
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qualitative review of clinical trials—randomized, nonrandom-
ized, and uncontrolled studies—examined resistance exer-
cise training in relation to metabolic health among patients 
with type 2 diabetes.127 Ten of these studies assessed BP. 
Investigators concluded that resistance exercise training 
resulted in beneficial changes in systolic BP, with benefits 
in diastolic BP observed less frequently. (The magnitude of 
reduction was not specified.) Thus, the review of evidence did 
not provide consistent evidence on resistance exercise training 
for BP reduction.
5.4.2.3. Combination of Aerobic and Resistance Exercise 
Training and BP
There have been no published meta-analyses or reviews 
specifically examining the effect of a combined regimen of 
aerobic exercise and resistance training on BP. However, in 
some of the meta-analyses and reviews described above, stud-
ies with aerobic and resistance components were included in 
pooled data related to aerobic exercise training.113,114
5.5. Physical Activity Recommendations
1. In general, advise adults to engage in aerobic physi-
cal activity to reduce LDL-C and non–HDL-C: 3 to 4 
sessions per week, lasting on average 40 minutes per 
session, and involving moderate- to vigorous-inten-
sity physical activity.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: A
Rationale: This recommendation was based on evidence from 
meta-analyses and reviews published from 2001 onward and 
rated fair to good. This is also consistent with the findings of 
the literature review conducted for the 2008 Physical Activity 
Guidelines Advisory Committee Report, in which it was found 
that it may require 12 metabolic equivalent task-hours per 
week of exercise to favorably influence LDL-C. The amount 
of physical activity recommended above for reducing LDL-C 
and non–HDL-C is congruent with the amount of physical 
activity recommended in 2008 by the federal government 
for overall health: “Most health benefits occur with at least 
150 minutes (2 hours and 30 minutes) a week of moderate-
intensity physical activity, such as brisk walking. Additional 
benefits occur with more physical activity.”99
2. In general, advise adults to engage in aerobic physi-
cal activity to lower BP: 3 to 4 sessions per week, last-
ing on average 40 minutes per session, and involving 
moderate- to vigorous-intensity physical activity.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: A
Rationale: This recommendation was based on evidence 
from meta-analyses and reviews rated fair to good that were 
published from 2001 onward, as well as the 2008 Physical 
Activity Guidelines Advisory Committee Report. The amount 
of physical activity recommended above for lowering BP is 
congruent with the amount of physical activity recommended 
in 2008 by the federal government for overall health: “Most 
health benefits occur with at least 150 minutes (2 hours and 
30 minutes) a week of moderate-intensity physical activity, 
such as brisk walking. Additional benefits occur with more 
physical activity.”99 It is worth noting that the present recom-
mendation is congruent with (ie, expends approximately the 
same amount of energy) but not identical to the 2008 federal 
guidelines. This is because the present recommendation is 
based on a review of meta-analyses of exercise in relation to 
BP only (hence, the specific regimens as used in the clinical 
trials), whereas the 2008 federal guidelines targeted overall 
health (ie, not just BP). Additionally, the 2008 federal guide-
lines for overall health make it clear that any amount of physi-
cal activity is healthful (“Some physical activity is better than 
none”), and that there is a dose-response relationship (“For 
most health outcomes, additional benefits occur as the amount 
of physical activity increases through higher intensity, greater 
frequency, and/or longer duration”).
5.6. Heart-Healthy Nutrition and Physical Activity 
Behaviors
See Table 17 for information on heart-healthy nutrition and 
physical activity behaviors.
Overall, the Work Group encourages heart-healthy nutrition 
and physical activity behaviors for the entire US adult popula-
tion as stated in the 2010 Dietary Guidelines for Americans 
and the 2008 Physical Activity Guidelines for Americans. The 
recommendations in Table 17 are a consensus of the Work 
Group, not a guideline, and are generally consistent with the 
2010 Dietary Guidelines for Americans and the 2008 Physical 
Activity Guidelines for Americans.
6. Gaps in Evidence and Future Research Needs
6.1. Diet
The extensive work of the Work Group served an addi-
tional purpose, and that was to identify important gaps in 
the knowledge of how lifestyle impacts CVD risk reduction. 
Table 17. Heart-Healthy Nutrition and Physical Activity 
Behaviors
Heart-Healthy Nutrition and Physical Activity Behaviors
The adult population should be encouraged to practice heart-healthy  
 lifestyle behaviors, including:
•	Consume a dietary pattern that emphasizes intake of vegetables, fruits,  
 and whole grains; includes low-fat dairy products, poultry, fish,  
legumes, nontropical vegetable oils, and nuts; and limits intake of sodium, 
sweets, sugar-sweetened beverages, and red meats.
– Adapt this dietary pattern to appropriate calorie requirements,  
personal and cultural food preferences, and nutrition therapy for 
other medical conditions (including diabetes).
– Achieve this pattern by following plans such as the DASH dietary 
pattern, the USDA Food Pattern, or the AHA Diet.
•	Engage in 2 h and 30 min per wk of moderate-intensity physical  
 activity, or 1 h and 15 min (75 min) per wk of vigorous-intensity aerobic 
physical activity, or an equivalent combination of  
moderate- and vigorous-intensity aerobic physical activity.  
Aerobic activity should be performed in episodes of at least  
10 min, preferably spread throughout the wk.132
•	Achieve and maintain a healthy weight. Refer to the 2013 Obesity Expert  
Panel Report for recommendations on weight loss and maintenance.5
AHA indicates American Heart Association; DASH, Dietary Approaches to Stop 
Hypertension; and USDA, US Department of Agriculture.
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Additional research is needed on the following topics related 
to diet:
•	 Interaction between dietary modification and statin 
treatment.
•	 Relative effects of saturated fats, monounsaturated fatty 
acids, polyunsaturated fatty acids, trans fatty acids, 
omega-3 fatty acids, and types of carbohydrates on lip-
ids, inflammation, microbiome, and other newer poten-
tial CVD risk factors.
•	 Relative effects of naturally occurring fiber (cereal 
[whole grains] and vegetable/fruit) and supplemental 
fiber on lipids, inflammation, microbiome, and other 
newer potential CVD risk factors.
•	 Effects of dietary cholesterol on LDL-C and HDL-C 
over the current ranges of cholesterol and saturated fat 
intakes (5th and 95th percentiles).
•	 Effects of minerals in combination (other than sodium) 
on BP.
•	 High-density lipoprotein function in studies that modify 
HDL-C by changes in diet.
•	 Is the minimal effect of dietary carbohydrate on plasma 
triglycerides harmful?
•	 The effect of sodium reduction in patients with diabetes, 
heart failure, and chronic kidney disease.
•	 Effect of dietary pattern and sodium intake in adults 
taking BP-lowering or lipid-lowering medications (eg, 
effects on BP/lipids, achieving BP/lipid goals, medica-
tion needs/costs, outcomes).
•	 Effect of dietary pattern and sodium intake in adults with 
CVD (eg, after myocardial infarction; after stroke; with 
coronary artery disease, heart failure, or chronic kidney 
disease).
•	 Strategies for effectively (and cost-effectively) imple-
menting these evidence-based recommendations. 
(How can primary care providers, health systems, 
public health agencies, local and federal govern-
ment, community organizations, and other stakehold-
ers help patients adopt these diet and sodium intake 
recommendations?)
•	 Increased understanding of racial/ethnic/socioeco-
nomic factors that may influence (a) effect of dietary 
pattern and sodium on BP and lipids, (b) adoption of 
diet/sodium recommendations, and (c) method of diet 
assessment.
6.2. Physical Activity
Additional research is needed on the following topics related 
to physical activity:
•	 Improved understanding of whether exercise performed 
at a lower intensity or dose, or different modes of exer-
cise, can impact these outcomes.
•	 Further understanding the characteristics of individu-
als for whom exercise of a certain dose or intensity can 
reduce LDL-C and non–HDL-C.
•	 Understand the source of the inconsistent findings to 
better understand under what conditions exercise can 
increase HDL-C or decrease triglycerides.
•	 Define the optimal dose of exercise that will result in the 
desired changes in lipids and lipoproteins and whether 
exercise performed at a lower intensity or dose, or differ-
ent modes of exercise, can impact these outcomes.
•	 Further understand the characteristics of individuals for 
whom exercise of a certain dose, intensity, or mode can 
increase HDL-C or reduce triglycerides.
•	 Clarify the shape of the dose-response curve between 
physical activity and BP.
•	 Expand the limited data on whether resistance exercise 
training lowers BP and whether a combination of aero-
bic and resistance exercise training offers any added BP 
lowering, compared with aerobic exercise only.
•	 Determine how diet and physical activity behave syner-
gistically with regard to lipids and BP.
•	 Determine the effect of physical activity in adults tak-
ing BP-lowering and/or lipid-lowering medications (eg, 
effects on BP/lipids, achieving BP/lipid goals, medica-
tion needs/costs, outcomes).
•	 Determine the effect of physical activity in adults with 
CVD (eg, after myocardial infarction; after stroke; with 
coronary artery disease, heart failure, or chronic kidney 
disease).
•	 Determine strategies for effectively (and cost-effec-
tively) implementing these evidence-based recom-
mendations. (How can primary care providers, health 
systems, public health agencies, local and federal gov-
ernment, community organizations, and other stake-
holders help patients adopt these physical activity 
recommendations?)
•	 Increase understanding of racial/ethnic/socioeconomic 
factors that may influence (a) effect of physical activity 
on BP and lipids and (b) adoption of physical activity 
recommendations.
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Correction
S100
In the article by Eckel et al, “2013 ACC/AHA Guideline on Lifestyle Management to Reduce 
Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines,” which published online November 12, 2013, and appears in the 
supplement to the June 24, 2014, issue of the journal (Circulation. 2014;129[suppl 2]:S76–S99), 
several corrections were needed.
These corrections have been made to the print version and to the current online version of the article, 
which is available at http://circ.ahajournals.org/lookup/doi/10.1161/01.cir.0000437740.48606.d1.
1.  On the title page, the first footnote paragraph now reads “This document was approved by 
the American College of Cardiology Board of Trustees and the American Heart Association 
Science Advisory and Coordinating Committee in November 2013. The Academy of Nutrition 
and Dietetics affirms the value of this guideline.” The footnote previously did not refer to the 
Academy of Nutrition and Dietetics.
2.  On the title page, Robert A. Guyton, MD, FACC, was listed as a member of the ACC/AHA Task 
Force. His name has been removed from the list of Task Force members.
3.  Throughout the article, the references have been renumbered.
4.  In Section 1.2.1, references have been added for the 2013 Blood Cholesterol and Obesity guide-
lines, references 4 and 5, respectively.
5.  In Table 5, the second section, the third recommendation for blood pressure read, “Advise adults 
who would benefit from BP lowering to…
3. a.  Consume no more than 2,400 mg of sodium/day;
b.  Further reduction of sodium intake to 1,500 mg/day is desirable since it is associated with 
even greater reduction in BP; and
c.  Reduce intake by at least 1,000 mg/day since that will lower BP, even if the desired sodium 
intake is not yet achieved.”
It has been changed to read, “Advise adults who would benefit from BP lowering to…
3. a.  Consume no more than 2 400 mg of sodium/d;
b.  Further reduction of sodium intake to 1 500 mg/d can result in even greater reduction in 
BP; and
c.  Even without achieving these goals, reducing sodium intake by at least 1 000 mg/d lowers 
BP.”
6.  In Section 4.3, the first sentence read, “In all, 34 studies (47 citations) satisfied the CQ2 inclu-
sion criteria and were rated good or fair quality.30,31,45,46,52-93” It has been changed to read, “In 
all, 34 studies (46 citations) satisfied the CQ2 inclusion criteria and were rated as good or fair 
quality.31,32,46,47,53-94”
7.  In Section 4.5, recommendation 3 read,
“3. Advise adults who would benefit from BP lowering to:
a.  Consume no more than 2 400 mg/day of sodium;
b.  Further reduction of sodium intake to 1 500 mg/day is desirable since it is associated with 
an even greater reduction in BP; and
c.  Reduce sodium intake by at least 1 000 mg/day since that will lower BP, even if the desired 
daily sodium intake is not yet achieved.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: B”
It has been changed to read,
“3. Advise adults who would benefit from BP lowering to:
a.  Consume no more than 2 400 mg of sodium/d;
b.  Further reduction of sodium intake to 1 500 mg/d can result in even greater reduction in 
BP; and
(Circulation. 2014;129[suppl 2]:S100-S101.)
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Correction  S101
c.  Even without achieving these goals, reducing sodium intake by at least 1 000 mg/d lowers BP.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: B”
8.  In Section 5.1, the first paragraph, a reference has been added to the last sentence: “In a recent 
analysis, it was estimated that by eliminating physical inactivity, 6% of coronary heart disease 
worldwide may be eliminated, and life expectancy of the world population may be increased 
by 0.68 years.104,105”
9.  In Section 6.1, introductory text has been added to the beginning of the bulleted list: “The exten-
sive work of the Work Group served an additional purpose, and that was to identify important 
gaps in the knowledge of how lifestyle impacts CVD risk reduction. Additional research is 
needed on the following topics related to diet:”
10.  In Section 6.2, introductory text has been added to the beginning of the bulleted list: “Additional 
research is needed on the following topics related to physical activity:”
11.  After the references, Key Words have been added: “AHA Scientific Statements ■ cardiovascu-
lar disease ■ blood cholesterol ■ blood pressure ■ nutrition ■ dietary patterns ■ dietary fats 
■ dietary sodium ■ physical activity
12.  In Appendix 1, the relevant RWI has been added for Janet de Jesus for 2013:
Committee 
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Employment Consultant Speaker’s 
Bureau
Ownership/ 
Partnership/ 
Principal
Personal 
Research
Expert 
Witness
Janet M. de Jesus, 
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of Research 
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2008–2012: 
None
2013: None
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None
2013: None
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2013: None
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None
2013: None
2008–2012: 
None
2013: None
13.  In Appendix 2, the following has been added to the footnote: “This table represents the rela-
tionships of reviewers with industry and other entities that were self-disclosed at the time of 
peer review. It does not necessarily reflect relationships with industry at the time of publica-
tion. To review the NHLBI and ACC/AHA’s current comprehensive policies for managing 
relationships with industry and other entities, please refer to http://www.nhlbi.nih.gov/guide-
lines/cvd_adult/coi-rwi_policy.htm and http://www.cardiosource.org/Science-And-Quality/
Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx.”
Correction
e326
In the article by Eckel et al “2013 AHA/ACC Guideline on Lifestyle Management to Reduce 
Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines,” which published online November 12, 2013, and appeared in the 
June 24, 2014, issue of the journal (Circulation. 2014;129[suppl 2]:S76-S99), a correction was needed.
1.  On the title page in the footnotes section, the fourth paragraph, the authors were listed out of 
order in the citation and the initials for Thomas A. Wadden were incorrect. The citation read,
Eckel RH, Jakicic JM, Ard JD, Hubbard VS, de Jesus JM, Houston Miller N, Lee I-M, 
Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden 
TW, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular 
risk: a report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation. 2014;129(suppl 2):S76–S99.
It now reads,
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee I-M, 
Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden 
TA, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular 
risk: a report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation. 2014;129(suppl 2):S76–S99.
These corrections have been made to the current online version of the article, which is available 
at http://circ.ahajournals.org/content/129/25_suppl_2/S76.
(Circulation. 2015;131:e326. DOI: 10.1161/CIR.0000000000000155.)
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